Evidence map›Paper›PMID 29796630›Full record

ArticleGlycobiology2018

Identification of serum glycoprotein ligands for the immunomodulatory receptor blood dendritic cell antigen 2.

Jong-Won Kim, James Budzak, Yu Liu, Sabine A F Jégouzo, Kurt Drickamer, Maureen E Taylor

Open access · hybridAbstract read
In one paragraph

Article in Glycobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. A type I interferon regulatory network for human plasmacytoid dendritic cells based on heparin, membrane-bound and soluble BDCA-2.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jong-Won KimDepartment of Life Sciences, Sir Ernst Chain Building, Imperial College, London, UK.
James BudzakDepartment of Life Sciences, Sir Ernst Chain Building, Imperial College, London, UK.
Yu LiuDepartment of Life Sciences, Sir Ernst Chain Building, Imperial College, London, UK.
Sabine A F JégouzoDepartment of Life Sciences, Sir Ernst Chain Building, Imperial College, London, UK.
Kurt DrickamerDepartment of Life Sciences, Sir Ernst Chain Building, Imperial College, London, UK.
Maureen E TaylorDepartment of Life Sciences, Sir Ernst Chain Building, Imperial College, London, UK.
Imperial College London · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K007718/1Wellcome TrustWellcome Trust 093599
6 · The paper itself

Abstract

Blood dendritic cell antigen 2 (BDCA-2) is a C-type lectin found on the surface of plasmacytoid dendritic cells. It functions as a glycan-binding receptor that downregulates the production of type I interferons and thus plays a role in oligosaccharide-mediated immunomodulation. The carbohydrate recognition domain in BDCA-2 binds selectively to galactose-terminated bi-antennary glycans. Because the plasmacytoid dendritic cells function in a plasma environment rich in glycoproteins, experiments have been undertaken to identify endogenous ligands for blood dendritic cell antigen 2. A combination of blotting, affinity chromatography and proteomic analysis reveals that serum glycoprotein ligands for BDCA-2 include IgG, IgA and IgM. Compared to binding of IgG, which was previously described, IgA and IgM bind with higher affinity. The association constants for the different subclasses of immunoglobulins are below and roughly proportional to the serum concentrations of these glycoprotein ligands. Binding to the other main serum glycoprotein ligand, α2-macroglobulin, is independent of whether this protease inhibitor is activated. Binding to all of these glycoprotein ligands is mediated predominantly by bi-antennary glycans in which each branch bears a terminal galactose residue. The different affinities of the glycoprotein ligands reflect the different numbers of these galactose-terminated glycans and their degree of exposure on the native glycoproteins. The results suggest that normal serum levels of immunoglobulins could downmodulate interferon stimulation of further antibody production.

Indexed as

Blood ProteinsGalactoseGlycoproteinsHumansLectins, C-TypeLigandsMembrane GlycoproteinsProtein BindingReceptors, ImmunologicBlood ProteinsCLEC4C protein, humanGalactoseGlycoproteinsLectins, C-TypeLigandsMembrane GlycoproteinsReceptors, Immunologic

Identifiers

PMID29796630
PMCPMC6054153
OpenAlexW2804887392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.